期刊文献+

双特异性磷酸酶1在子宫内膜样腺癌组织中表达及与预后的关系 被引量:6

Relationship between the expression of dual specificity phosphatase-1 and the prognosis of endometrioid adenocarcinoma
原文传递
导出
摘要 目的 探讨双特异性磷酸酶1(DUSP1)在子宫内膜样腺癌组织中的表达与预后的关系.方法 采用免疫组织化学方法检测DUSP1在81例手术切除的子宫内膜样腺癌组织标本中的表达,并分析DUSP1与临床病理特征及预后的关系.结果 81例中59例(72.84%)阳性表达,22例阴性表达.DUSP1与手术分期、病理分级、肌层浸润、ER及PR相关(P<0.05),与淋巴结转移无关.Kaplan-Meier生存分析显示DUSP1表达阳性组与阴性组5年无瘤生存率分别为98.2%和76.0%(P<0.05).COX回归分析显示DUSP1与PR为子宫内膜样腺癌预后的独立危险因素,DUSP1阴性与阳性表达的相对危险度为21.2.Spearman相关分析显示DUSP1与PR的表达呈正相关(r=0.256,P<0.05).结论 DUSP1表达下降可作为子宫内膜癌预后不良的潜在标志物. Objective To clarify the relationship between the expression of dual specificity phosphatase-1 ( DUSP1 ) and the prognosis of endometrioid adenocareinoma. Methods The expression of DUSP1 was determined by immunohistoehemical staining in specimens from 81 patients with endometrial carcinoma undergoing surgical resection. The relationship between DUSP1 expression, clinicopathological factors and prognosis were further evaluated. Results In 81 endometrioid carcinoma samples, 59 (72. 84% ) cases were positive while 22 negative. Except for lymph node metastasis, the expression of DUSP1 was correlated with FIGO stage, tumor grade, myometrial invasion and the expressions of estrogen receptor (ER) and progesterone receptor (PR) (P 〈 0. 05 ). Kaplan-Meier analysis showed that patients with a positive DUSP1 expression had significantly prolonged 5-year disease-free survival rates of 98.2% and 76. 0% respectively ( P 〈 0. 05 ). And COX regression analysis revealed that the expressions of DUSP1 and PR were independent prognostic indicators of endometrioid carcinoma, the HR ( hazard ratio) of DUSP1 negative expression was 21.2. Spearman analysis further showed that the expression of DUSP1 was positively correlated with PR ( r = 0. 256, P 〈 0. 05 ). Conclusion DUSP1 may be a potential negative prognostic indicator for endometrioid adenocarcinoma.
机构地区 [
出处 《中华医学杂志》 CAS CSCD 北大核心 2013年第31期2493-2495,共3页 National Medical Journal of China
基金 教育部博士点基金(20090001110085)
关键词 双特异性磷酸酶1 子宫内膜癌 预后 Dual specificity phosphatase 1 Endometrial neoplasms Prognosis
  • 相关文献

参考文献10

  • 1Plataniotis G,Castiglione M.Endometrial cancer:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up.Ann Oncol,2010,21 (Suppl 5):v41-45.
  • 2Kitchener HC,Trimble EL Endometrial cancer state of the science meeting.Int J Gynecol Cancer,2009,19:134-140.
  • 3Markova I,Duskova M,Lubusky M,et al.Selected immunohistochemical prognostic factors in endometrial cancer.Int J Gynecol Cancer,2010,20:576-582.
  • 4Chen Y,Yao Y,Zhang L,et al.cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer.Exp Mol Patho1,2011,91:373-384.
  • 5Venugopal SK,Chen J,Zhang Y,et al.Role of MAPK phosphatase-1 in sustained activation of JNK during ethanol-induced apoptosis in hepatocyte-like VL-17A cells.J Biol Chem,2007,282:31900-31908.
  • 6Friedrichs K,Gluba S,Eidtmann H,et al.Overexpression of p53 and prognosis in breast cancer.Cancer,1993,72:3641-3647.
  • 7Tsujita E,Taketomi A,Gion T,et al.Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma.Oncology,2005,69:342-347.
  • 8Vicent S,Garayoa M,Lopez-Picazo JM,et al.Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.Clin Cancer Res,2004,10:3639-3649.
  • 9Gu C,Zhang Z,Yu Y,et al.Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.Cancer Sci,2011,102:557-564.
  • 10Chen CC,Hardy DB,Mendelson CR.Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1).J Biol Chem,2011,286:43091-43102.

同被引文献101

  • 1王志启,王建六,郭健,魏丽惠.内分泌辅助治疗子宫内膜癌的临床意义[J].中华医学杂志,2005,85(34):2414-2419. 被引量:21
  • 2刘慧姝,张红霞.子痫前期的病因学新进展[J].实用医学杂志,2006,22(23):2705-2706. 被引量:17
  • 3Siegel R, Ma J, Zou Z, et al. Cancer statistics ,2014 [ J ]. CA Cancer J C1in,2014,64( 1 ) :9-29.
  • 4Micalizzi I)S, Farabaugh SM, Ford HL. Epithelial-mesen- chymal transition in cancer:parallels between normal de- velopment and tumor progression [ J ]. J Mammary Gland Biol Neoplasia, 2010,15 ( 2 ) : 117-134.
  • 5Bokhman JV. Two pathogenetic types of endometrial carci- noma[ J ]. Gynecol Oncol, 1983,15 ( 1 ) : 10-17.
  • 6Hayashida T, Jinno H, Kitagawa Y, et al. Cooperation of cancer stem cell properties and epithelial-mesenchymal transition in the establishment of breast cancer metastasis [J]. J Oncol,2011,59(1) :14-27.
  • 7Chai JY, Modak C, Mouazzen W, et al. Epithelial or mes- enchymal: Where to draw the line? [J ]. BioScience Trends, 2010,4 ( 3 ) : 130-142.
  • 8Zhao G, Nie Y, Lv M, et al. ERl3-mediated estradiol en- hances epithelial mesenchymal transition of lung adeno- carcinoma through increasing transcription of midkine [ J ].Mol Endocrinol, 2012,26 ( 8 ) : 1304 - 1315.
  • 9Wang KH, Kao AP, Lin TC, et al. Promotion of epithelial- mesenchymal transition and tumor growth by 17[3-estradiol in an ER (+)/HER2 (+) cell line derived from human breast epithelial stem cells [ J] Biotechnol Appl Bioehem, 2012,59 (3) :262-267.
  • 10Pieotto G, Massheimer V, Boland R. Acute stimulation of intestinal cell calcium influx induced by 17 beta-estradiol via the cAMP messenger system[ J]. Mol Cell Endocrinol, 1996.119(2) :129-134.

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部